0001140361-14-017291.txt : 20140423 0001140361-14-017291.hdr.sgml : 20140423 20140423100227 ACCESSION NUMBER: 0001140361-14-017291 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20140423 DATE AS OF CHANGE: 20140423 EFFECTIVENESS DATE: 20140423 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Corbus Pharmaceuticals Holdings, Inc. CENTRAL INDEX KEY: 0001595097 IRS NUMBER: 464348039 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-216074 FILM NUMBER: 14777716 BUSINESS ADDRESS: STREET 1: 142 WEST 57TH STREET STREET 2: SUITE 4A CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 646-367-5905 MAIL ADDRESS: STREET 1: 142 WEST 57TH STREET STREET 2: SUITE 4A CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: SAV Acquisition Corp DATE OF NAME CHANGE: 20131220 D 1 primary_doc.xml X0707 D LIVE 0001595097 Corbus Pharmaceuticals Holdings, Inc. 142 WEST 57TH STREET SUITE 4A NEW YORK NY NEW YORK 10019 646-367-5905 DELAWARE None SAV Acquisition Corp Corporation true 2013 David Hochman 142 W. 57th Street Suite 4A New York NY NEW YORK 10019 Director Yuval Cohen 508 Dudley Road Newton MA MASSACHUSETTS 02459 Executive Officer Director Mark Tepper 508 Dudley Road Newton MA MASSACHUSETTS 02459 Executive Officer Sean Moran 508 Dudley Road Newton MA MASSACHUSETTS 02459 Executive Officer Robert Zurier 303 Martom Rd Wyckoff NJ NEW JERSEY 07481 Executive Officer Alan Holmer 6 Knight Road Farmingham MA MASSACHUSETTS 01701 Director Investing Decline to Disclose 06b false 2014-04-11 false true true true At closing, our wholly owned subsidiary merged with and into JB Therapeutics, Inc. and JB became our wholly owned subsidiary. The stockholders of JB received 9,000,000 shares of our stock and 917,612 warrants exercisable at $1.00 per share. 0 Aegis Capital Corp. 15007 None None 810 7th Ave 18th Floor New York NY NEW YORK 10019 All States false 13000000 6310000 6690000 Reflects only private placement consideration. Contemporaneously with the merger, we completed a private placement of stock and warrants. Includes over allotment option. false 45 1300000 true 0 true Placement Agent is entitled to receive 10% cash and certain non cash consideration based on the aggregate amount sold in the offering. Estimated amount of sales commissions assumes maximum offering sold. Includes fees paid on over allotment option. 0 true Some of the proceeds may be used for general working capital purposes which may include payment of salaries and other fees to those listed in Item 3. false Corbus Pharmaceuticals Holdings, Inc. /s/ Yuval Cohen Yuval Cohen Chief Executive Officer 2014-04-23